

## Renascience to open branch lab of Northwestern University Longevity Institute in Japan

The TREx-Longevity Lab will conduct multidimensional phenotyping to measure the biological age of Japanese

24 January 2025 | News

| people, | • | ,, <b>c</b> | • |  |
|---------|---|-------------|---|--|
|         |   |             |   |  |
|         |   |             |   |  |
|         |   |             |   |  |
|         |   |             |   |  |
|         |   |             |   |  |
|         |   |             |   |  |
|         |   |             |   |  |

Japanese firm Renascience has concluded a joint research agreement on ageing with Prof. Douglas E. Vaughan, Director of the Potocsnak Longevity Institute at Northwestern University (Chicago, USA), and have agreed to open its branch at the Tohoku University Renascience Open Innovation Lab (TREx), its open innovation hub within Tohoku University, Japan.

Developed countries, including Japan, are facing an ultra-ageing population, and ageing is an urgent issue not only medically but also socially. The company aims to clarify cellular senescence at the molecular level, develop new medicines to treat diseases associated with tissue and individual ageing, and ultimately contribute to medical innovation to improve human aging. For many years, Renascience have been conducting pre-clinical studies in animals and epidemiological surveys of long-lived families in collaboration with Professor Douglas E. Vaughan, Northwestern University.

The Potocsnak Longevity Institute at Northwestern University is working to accurately measure human biological age and conduct clinical trials to evaluate pharmaceuticals that may slow the ageing process.

The TREx-Longevity Lab will conduct multidimensional phenotyping to measure the biological age of Japanese people, ageing analysis of human organs (cardiovascular, respiratory, neurocognitive, metabolic, musculoskeletal), and cutting-edge molecular profiling of aging biomarkers (epigenome, proteome, transcriptome), and will enroll a cross-sectional cohort of individuals from many ethnic and socioeconomic backgrounds across multiple countries, including the United States and Japan. In addition, the company plans to conduct clinical trials to evaluate our pharmaceutical product that may control ageing (RS5614).